Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy

Table 3

Maternal outcomes of pregnant women using insulin glargine versus NPH among the studies selected for meta-analysis.

Maternal outcomes	Number of; studies	Insulin glargine		NPH		Mean difference*/; odds ratio**	95% confidence limits
		Unadjusted mean/events	Number of; patients	Unadjusted mean/events	Number of; patients		Lower limit	Upper limit
Weight at delivery (kg)	4	93.3	167	92.1	179	−0.82*	−6.79	5.15
Weight gain (kg)	5	15.1	230	15	265	0.16*	−1.03	1.35
HbA1c—1st trimester (%)	4	7.67	143	7.65	158	−0.08*	−0.64	0.49
HbA1c—3rd trimester (%)	6	6.7	252	6.8	286	−0.01*	−0.07	0.05
Severe hypoglycemia (n)	4	9	155	20	205	0.84**	0.18	3.79
Pre-eclampsia (n)	8	26	331	40	371	0.55**	0.23	1.32
Cesarean section (n)	6	199	284	231	324	1.04**	0.72	1.52
Gestational hypertension (n)	4	9	155	23	205	0.49**	0.20	1.20

*Mean difference: insulin glargine versus NPH insulin; **Odds ratio: insulin glargine/NPH insulin.